Muller mistakes: The linear no-threshold (LNT) dose response and US EPA's cancer risk assessment policies and

Edward J Calabrese1, Paul B Selby2

  • 1School of Public Health and Health Sciences, Amherst, MA, 01003, USA; Department of Environmental Health Sciences, Amherst, MA, 01003, USA; Morrill I, N344, Amherst, MA, 01003, USA; University of Massachusetts, Amherst, MA, 01003, USA.

PubMed

Insights

This study reveals six conceptual errors by Hermann Muller that led to the linear no-threshold (LNT) model for cancer risk assessment. Contemporary research highlights significant limitations of this widely used LNT model.

Area of Science:

  • Environmental Science
  • Toxicology
  • Radiation Biology

Background:

  • Hermann Muller's work significantly influenced environmental policies and risk assessment practices.
  • The linear no-threshold (LNT) model has been historically applied globally for cancer risk assessments.
  • Current scientific understanding questions the universal applicability of the LNT model.

Purpose of the Study:

  • To identify and analyze six major conceptual scientific errors in Hermann Muller's work.
  • To explain how these errors contributed to the development of the LNT dose-response model.
  • To support ongoing research demonstrating the limitations of the LNT model in cancer risk assessment.

Main Methods:

  • Historical analysis of Hermann Muller's scientific contributions and conceptual frameworks.
  • Review of the foundational principles and historical implementation of the LNT model.
  • Synthesis of contemporary research evaluating the LNT model's efficacy and limitations.

Main Results:

  • Six key conceptual scientific errors in Muller's work have been identified.
  • These errors demonstrably influenced the establishment of the LNT dose-response model.
  • The paper provides evidence supporting the significant limitations of the LNT model for risk assessment.

Conclusions:

  • Muller's conceptual errors have had a lasting, albeit flawed, impact on environmental and radiation risk policies.
  • The LNT model, stemming from these errors, requires critical re-evaluation for accurate cancer risk assessment.
  • This research underscores the need for updated scientific models that better reflect biological realities.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.2K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.6K
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
434
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
7.0K